RPL26

Large ribosomal subunit protein uL24 · P61254 · RPL26 on Sugi Atlas →

3,617 patent compounds predicted against RPL26, 1,884 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL26 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Serum IL 26 as a Marker of Disease Activity in SLE	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Mitoquines in COPD	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a RPL26 binder may also engage these)

Protein	Name	Similarity
P12749	—	1.000	P12749 →
P61255	—	0.996	P61255 →
G1SQH0	—	0.996	G1SQH0 →
Q9UNX3	—	0.996	Q9UNX3 →
P61257	—	0.992	P61257 →
P61256	—	0.991	P61256 →
P47832	—	0.984	P47832 →
Q2I0I6	—	0.973	Q2I0I6 →
Q6QN05	—	0.949	Q6QN05 →
A5JSS2	—	0.947	A5JSS2 →
G1SHQ2	—	0.944	G1SHQ2 →
P49666	—	0.943	P49666 →
RPL21	Large ribosomal subunit protein eL21	0.941	landscape →
P20280	—	0.941	P20280 →
O09167	—	0.940	O09167 →
RPL27A	Large ribosomal subunit protein uL15	0.915	landscape →
G1SVB0	—	0.915	G1SVB0 →
A6H769	—	0.915	A6H769 →
P18445	—	0.913	P18445 →
Q3SZQ6	—	0.913	Q3SZQ6 →
RPL32	Large ribosomal subunit protein eL32 (60S rib	0.912	landscape →
G1SNY0	—	0.912	G1SNY0 →
Q5REY2	—	0.911	Q5REY2 →
Q5R1X0	—	0.910	Q5R1X0 →
Q4R723	—	0.909	Q4R723 →
P14115	—	0.909	P14115 →
Q56K03	—	0.908	Q56K03 →
Q56JV1	—	0.908	Q56JV1 →
P62912	—	0.907	P62912 →
Q76KA3	—	0.907	Q76KA3 →